ALNYLAM PHARMACEUTICALS, INC. Payments for (Proceeds from) Derivative Instrument, Financing Activities
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments for (Proceeds from) Derivative Instrument, Financing Activities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for the quarter ending 2025-12-31 was -$64.82M, a 1327.46% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for the quarter ending 2025-09-30 was $32.08M, a 507.38% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for the quarter ending 2025-06-30 was $27.46M, a 2042.36% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for the quarter ending 2025-03-31 was $5.28M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for fiscal 2024 was $8.79M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for fiscal 2023 was -$24.67M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) derivative instrument, financing activities for fiscal 2022 was -$31.00M.
| Period end | Payments for (Proceeds from) Derivative Instrument, Financing Activities 3 month | Payments for (Proceeds from) Derivative Instrument, Financing Activities 6 month | Payments for (Proceeds from) Derivative Instrument, Financing Activities 9 month | Payments for (Proceeds from) Derivative Instrument, Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$64.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$32.75M derived: sum of 2 quarters · filed 2026-02-12 | -$5.28M derived: sum of 3 quarters · filed 2026-02-12 | $0.00 10-K · filed 2026-02-12 |
| 2025-09-30 | $32.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $59.54M derived: sum of 2 quarters · filed 2025-10-30 | $64.82M 10-Q · filed 2025-10-30 | $70.10M derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-06-30 | $27.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $32.75M 10-Q · filed 2025-07-31 | $38.03M derived: sum of 3 quarters · filed 2026-02-12 | $43.31M derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-03-31 | $5.28M 10-Q · filed 2025-05-01 | $10.56M derived: sum of 2 quarters · filed 2026-02-12 | $15.84M derived: sum of 3 quarters · filed 2026-02-12 | $17.13M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $10.56M derived: sum of 2 quarters · filed 2026-02-12 | $11.84M derived: sum of 3 quarters · filed 2026-02-12 | $8.79M 10-K · filed 2026-02-12 |
| 2024-09-30 | $5.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.56M derived: sum of 2 quarters · filed 2025-10-30 | $3.51M 10-Q · filed 2025-10-30 | -$4.82M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$1.77M 10-Q · filed 2025-07-31 | -$10.10M derived: sum of 3 quarters · filed 2026-02-12 | |
| 2024-03-31 | -$3.05M 10-Q · filed 2025-05-01 | -$11.39M derived: sum of 2 quarters · filed 2026-02-12 | ||
| 2023-12-31 | -$8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$24.67M 10-K · filed 2026-02-12 | ||
| 2023-09-30 | -$16.33M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | -$31.00M 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |